Lower Risks of Dementia, Stroke, and Mortality Associated with GLP-1 Receptor Agonists in Type 2 Diabetes and Obesity

A recent study published in July 2025 in JAMA Network Open reveals that adults with type 2 diabetes and obesity who are treated with glucagon-like peptide 1 receptor agonists (GLP-1 RAs) experience a significant reduction in the risks of developing dementia, ischemic stroke, and overall mortality compared to those on other diabetic medications. The research analyzed electronic health records of over 60,000 individuals, ensuring a balanced comparison between those using GLP-1 RAs such as semaglutide and tirzepatide and those on other antidiabetic drugs like metformin, sulfonylureas, DPP-4 inhibitors, SGLT2 inhibitors, thiazolidinediones, and alpha-glucosidase inhibitors.

Participants were followed over seven years, and the findings showed that users of GLP-1 RAs had hazard ratios indicating a lowered risk for dementia (0.63), ischemic stroke (0.81), and death from any cause (0.70). Notably, the protective effects were more pronounced among individuals aged 60 and above, women, and those with a body mass index ranging from 30 to 40. However, the study did not observe significant differences in the risks for Parkinson's disease or intracerebral hemorrhage.

The authors suggest that these outcomes point toward a potential role of GLP-1 RAs in reducing neurodegenerative and cerebrovascular risks in high-risk populations, emphasizing the importance of these medications not just for glycemic control but also for their broader neurological and cardiovascular benefits.

Source: https://medicalxpress.com/news/2025-07-dementia-ischemic-mortality-glp-receptor.html